Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Planta Med ; 2024 May 16.
Article in English | MEDLINE | ID: mdl-38754434

ABSTRACT

Taxol (common name: paclitaxel) is an extremely important component of drugs for the treatment of various cancers. Thirty years after the discovery of its effectiveness, a metabolic precursor of Taxol (10-deacetylbaccatin III) is still primarily extracted from needles of European yew trees. In order to meet the considerable demand, hopes were pinned on the possibilities of biotechnological production from the very beginning. In 1993, as if by chance, Taxol was supposedly discovered in fungi that grow endobiotically in yew trees. This finding aroused hopes of biotechnological use to produce fungal Taxol in large quantities in fermenters. It never came to that. Instead, a confusing flood of publications emerged that claimed to have detected Taxol in more and more eukaryotic and even prokaryotic species. However, researchers never reproduced these rather puzzling results, and they could certainly not be applied on an industrial scale. This paper will show that some of the misguided approaches were apparently based on a seemingly careless handling of sparse evidence and on at least questionable publications. Apparently, the desired gold rush of commercial exploitation was seductive. Scientific skepticism as an indispensable core of good scientific practice was often neglected, and the peer review process has not exerted its corrective effect. Self-critical reflection and more healthy skepticism could help to reduce the risk of such aberrations in drug development. This article uses this case study as a striking example to show what can be learned from the Taxol case in terms of research ethics and the avoidance of questionable research practices.

2.
J Perinat Med ; 51(6): 763-768, 2023 Jul 26.
Article in English | MEDLINE | ID: mdl-36935569

ABSTRACT

Apparently, there is a broad scope of legal issues affecting the work with embryonic stem cells. I cannot address them all. I would like to focus on two fields of law and discuss, rather in the overview, some salient issues of German constitutional and administrative law framing the scientific research process. Compared to the sophisticated scientific work we discuss here, legal arguments and operations remain blunt and awkward, addressing rather the identity of a society than the fluid frontiers of science and technology.


Subject(s)
Embryonic Stem Cells , Stem Cell Research , Humans , Stem Cell Research/legislation & jurisprudence
SELECTION OF CITATIONS
SEARCH DETAIL
...